In the lab, José demonstrated the relevance of blocking EGFR in lung and breast cancer [1–3], and in a work that was published in JNCI 1993, he provided the rationale for combining an anti-EGFR antibody therapy (cetuximab) with chemotherapy. Here, EGFR is linked to breast cancer.